What is VDx?
Operating at the intersection of clinical veterinary medicine and advanced pathology, VDx provides critical diagnostic support through expert analysis of biopsy and cytology samples. With a legacy spanning over 24 years, the organization serves as a vital partner to clinicians, pharmaceutical entities, and academic institutions. Their core competency lies in delivering high-fidelity histopathology and pathology services, which are essential for the development of medical devices and the advancement of veterinary therapeutic protocols. By maintaining a team of board-certified pathologists, VDx ensures that its diagnostic reporting meets the rigorous standards required by the biotech and pharmaceutical research communities.
How much funding has VDx raised?
VDx has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in VDx
PPP
Public-Private Partnership
What's next for VDx?
With this late-stage capital infusion, VDx is expected to prioritize the scaling of its diagnostic throughput and the integration of enhanced digital pathology workflows. The strategic focus will likely shift toward deepening its penetration within the medical device and pharmaceutical research markets, where demand for high-quality, reliable pathology support remains robust. As the company navigates its next phase of growth, the emphasis will remain on maintaining diagnostic excellence while potentially exploring technological upgrades to its laboratory information systems to better serve its diverse client base in Northern California and beyond.
See full VDx company page
